Diffuse alveolar hemorrhage (DAH) is a recognized pulmonary complication in the setting of hematopoietic STC (HSCT). DAH after HSCT is often fatal, but the exact etiology remains unclear. DAH after HSCT is reported in 1-5% of autologous graft recipients and in 3-7% of allogeneic graft recipients. [1] [2] [3] [4] Umbilical cord blood transplantation (CBT) from unrelated donors has recently increased in popularity for adult patients with hematological diseases who have no other suitable donor. However, DAH in the setting of post CBT has not been discussed in detail. 4 We describe herein, a case of a patient with DAH after CBT who was successfully treated with relatively low-dose steroid therapy using prednisolone at 1 mg/kg/day.
A 50-year-old man was admitted to our hospital with general fatigue and anemia in February 2008. On admission, physical examination showed normal results, including lymph nodes and spleen size. Complete blood count showed a WBC count of 1.3 Â 10 3 per ml with 12% neutrophils, hemoglobin concentration of 6.1 g/dl and a plt count of 9.1 Â 10 4 per ml. BM examination showed hypercellularity and dysplasia with increased myeloblasts (15.2%). Myelodysplastic syndrome-refractory anemia with excess blasts was thus diagnosed. The patient was considered a candidate for HSCT. As no HLA-matched BM donors were identified, the patient underwent CBT from an unrelated male donor in cytarabine with concomitant administration of recombinant human granulocyte CSF. GVHD prophylaxis consisted of CYA and short-term MTX. Heparin was also administered at 5000 U/day for prophylaxis of venoocclusive disease. Prophylactic plt support was given with a threshold of 2.0 Â 10 4 per ml. Intravenous Ig was administered from day À1 to day 100 when serum Ig level was o5 g/l (500 mg/dl). To facilitate neutrophil engraftment, granulocyte CSF was administered i.v. at 5 mg/kg/day from day 1 after CBT. A neutrophil count consistently above 0.5 Â 10 3 per ml was achieved by day 24. A skin rash spread over 50% of the entire body surface, suggestive of Grade II acute GVHD, appeared on day 18, but this clinical presentation was controlled with an i.v. administration of hydrocortisone at 100 or 200 mg/day. On day 22, the patient developed progressive exertional dyspnea without high fever or hemoptysis. Physical examination revealed slight coarse crackles, particularly in the left upper lung. Laboratory examination revealed a low plt count (1.9 Â 10 4 per ml), and disseminated intravascular coagulation was excluded on the basis of fibrinogen levels (481 mg/ dl), fibrin degradation products (3.3 mg/ml) and the crosslinked fragment, D-dimer (2.1 mg/ml). Arterial blood gas values while breathing room air were as follows: PaO 2 (65.4 Torr); PaCO 2 (36.2 Torr); pH 7.514 and an abnormal alveolar-arterial oxygen gradient (39.4 Torr). Chest radiography showed diffuse air-space consolidation with reticulonodular infiltration, particularly in the left upper field. Computed tomography of the chest revealed sparsely distributed ground-glass opacification of alveolar spaces with patchy consolidation throughout bilateral lung fields ( Figure 1 ). Bronchoalveolar lavage fluid was bloody, with 97% macrophages, 2% lymphocytes and 1% neutrophils. No infectious agents including bacteria, CMV, human herpesvirus-6, Candida, Aspergillus or Pneumocystis jiroveci were identified from bronchoalveolar lavage fluid. These findings led to a diagnosis of DAH. Steroid therapy using prednisolone at 1 mg/kg/day was initiated on day 23, and prophylactic plt support was given with a threshold of 5.0 Â 10 4 per ml, leading to a gradual improvement of hypoxemia. Prednisolone was continued at 1 mg/kg/day for 2 weeks, and a striking clinical improvement was observed. The dose was then tapered weekly by 5 mg. Acute GVHD involving the skin gradually resolved after initiating prednisolone. A computed tomography scan on day 37 revealed a gradual improvement and the clinical signs continued to resolve (Figure 1 ). Computed tomography on day 65 was markedly improved (Figure 1) . A broadspectrum antibiotic agent (meropenem) and an antifungal agent (micafungin) had been administered because of febrile neutropenia for 2 weeks before the onset of DAH. Quantitative PCR analysis of the serum showed an increased human herpesvirus-6 DNA titer of 390 000 copies/ml (normal, o100 copies/ml) on day 12; therefore, administration of 90 mg/kg of foscarnet sodium was initiated on day 14. Ribavirin was started at 600 mg because of adenovirus-associated hemorrhagic cystitis characterized by frequent urination, dysuria and macroscopic hematuria on day 27. These symptoms improved within 1 week. Moreover, positive results for CMV antigenemia on days 54 and 103 prompted two courses of preemptive therapy with ganciclovir. Complete donor chimerism of BM mononuclear cells was confirmed using a PCR method on day 36, and the patient remained in remission until the last follow-up evaluation on day 104. He experienced recurrent adenovirus-associated hemorrhagic cystitis on day 131, but could not take oral ribavirin because of difficulties with oral intake. He died on day 141 from interstitial pneumonia and subsequent multiple organ failure.
Diffuse alveolar hemorrhage is one of the early complications after HSCT, and is unrelated to low plt counts. Factors predictive of increased incidence of alveolar hemorrhage after HSCT include older age, use of myeloablative conditioning, infections (particularly respiratory infections) and presence of severe acute GVHD. [1] [2] [3] [4] 5 The underlying undetected infections have been considered to have a role in the pathogenesis of DAH in some reports. [1] [2] [3] [4] 6 One such report described an association between infections and hemorrhagic complications in an autopsy series. 6 Although some reports have stated that high-dose corticosteroids cannot modify the poor outcomes associated with DAH, 3 high-dose corticosteroids have often been considered to be the treatment of choice for DAH. 7 Given that the mechanisms of DAH are probably associated with cytokine release associated with engraftment and GVHD and the presence of airway inflammation, this choice may be reasonable. From this perspective, cord blood generally elicits a lower incidence of GVHD than do other types of grafts, such as BM or peripheral blood, probably because of its immature nature. DAH in the setting of CBT might thus be successfully treated using a relatively low dose of corticosteroid. It is also desirable to avoid high-dose corticosteroid therapy as much as possible in the setting of CBT, as rates of virus reactivation are higher after CBT compared with after HSCT using other stem cell sources.
We have described herein, a patient with DAH after CBT who was successfully treated with a relatively low dose of corticosteroid, using prednisolone at 1 mg/kg/day. Optimal doses of corticosteroids in the setting of DAH after CBT can only be definitively clarified by larger studies with that specific aim.
